Literature DB >> 16828340

Changes in connexin 43, metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy in dogs.

Jing-quan Zhong1, Wei Zhang, Haiqing Gao, Yan Li, Ming Zhong, Duoling Li, Cheng Zhang, Yun Zhang.   

Abstract

OBJECTIVE: To study changes in connexin, metalloproteinase and tissue inhibitor of metalloproteinase levels during tachycardia-induced cardiomyopathy (TIC).
METHODS: Canine models of TIC were established by rapid right atrial pacing at 350-400 beats per min for 8 weeks in 11 dogs, six dogs acted as a sham operation group. Echocardiography, left ventricular pressure and its first derivation with time (positive and negative maximum, dp/dtmax, -dp/dtmax), and intracardiac electrograms were recorded before and after rapid pacing at 1, 4 and 8 weeks. Data were acquired in sinus rhythm. Ultrastructural changes in left ventricular tissue were observed by transmission electron microscope. Connexin 43 (Cx43) levels in the left ventricular myocardium were measured by confocal laser microscopy. The relative abundance of matrix metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP-2) were studied by immunoblotting. RESULT AND
CONCLUSIONS: (1) Ventricular dilatation and systolic dysfunction occurred after 1 week of rapid right atrial pacing. (2) There was structural damage to the myofibrils, mitochondria, and the sarcoplasmic reticulum with intercalated disk discontinuity. (3) Levels of Cx43 decreased significantly and gap junction remodelling occurred during TIC. (4) TIC may result from several mechanisms, such as ultrastructural changes or gap junction and matrix remodelling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828340     DOI: 10.1016/j.ejheart.2006.04.014

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

1.  Dynamic alterations of connexin43, matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 during ventricular fibrillation in canine.

Authors:  Jing Wang; Jing-sha Li; Hong-zhen Liu; Shao-lei Yi; Guo-ying Su; Yun Zhang; Jing-quan Zhong
Journal:  Mol Cell Biochem       Date:  2014-03-18       Impact factor: 3.396

Review 2.  Atrial fibrillation and heart failure: cause or effect?

Authors:  Christina Luong; Marion E Barnes; Teresa S M Tsang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 3.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

4.  Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.

Authors:  Efrat Kurtzwald-Josefson; Edith Hochhauser; Guy Katz; Eyal Porat; Jonathan G Seidman; Christine E Seidman; Yelena Chepurko; Asher Shainberg; Michael Eldar; Michael Arad
Journal:  J Appl Physiol (1985)       Date:  2012-10-04

5.  Acetylation mediates Cx43 reduction caused by electrical stimulation.

Authors:  Viviana Meraviglia; Valerio Azzimato; Claudia Colussi; Maria Cristina Florio; Anna Binda; Alice Panariti; Khaled Qanud; Silvia Suffredini; Laura Gennaccaro; Michele Miragoli; Andrea Barbuti; Paul D Lampe; Carlo Gaetano; Peter P Pramstaller; Maurizio C Capogrossi; Fabio A Recchia; Giulio Pompilio; Ilaria Rivolta; Alessandra Rossini
Journal:  J Mol Cell Cardiol       Date:  2015-08-08       Impact factor: 5.000

6.  MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma.

Authors:  Xiao Cong Zeng; Lang Li; Hong Wen; Qi Bi
Journal:  Mol Med Rep       Date:  2016-05-04       Impact factor: 2.952

7.  Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor γ.

Authors:  Xiao-Cong Zeng; Xing-San Li; Hong Wen
Journal:  BMC Cardiovasc Disord       Date:  2013-06-05       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.